Administration of convalescent plasma within nine days after symptom onset can reduce risk of COVID-19-linked hospitalization
Enhanced External Counterpulsation Eases ‘Long COVID’
Improvements seen in symptoms of fatigue, breathing difficulties, 6-minute walk test with EECP treatment
COVID-19 Convalescent Plasma Seems Safe for High-Risk Children
Recipient plasma neutralization titers were 6.2 percent of donor titers as early as 30 minutes after transfusion
COVID-19 Convalescent Plasma No Benefit for Most Patients
No association with clinical outcomes for typical patients; heterogeneity of treatment effect sizes seen across baseline characteristics
Casirivimab + Imdevimab Prevents Progression to Symptomatic COVID-19
For asymptomatic SARS-CoV-2-positive individuals living with infected household contact, combo cuts incidence of symptomatic COVID-19
Convalescent Plasma Not Efficacious in Hospitalized COVID-19 Patients
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
Convalescent Plasma Not Recommended in COVID-19
Guideline Development Group strongly recommends against its use in nonsevere COVID-19, recommends against use in severe, critical illness
Convalescent Plasma Unlikely to Improve Outcomes in Severe COVID-19
Likelihood of improvement in organ support-free days low in critically ill adults with COVID-19 receiving convalescent plasma
No Benefit Found for COVID-19 Convalescent Plasma in High-Risk Outpatients
Disease progression was not reduced with convalescent plasma for outpatients aged 50 years or older with one or more risk factors
Convalescent Plasma May Cut Deaths in Hematologic Cancer and COVID-19
Lower 30-day mortality seen in hospitalized adults, including those admitted to ICU, requiring mechanical ventilation